February 2021

1) A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine (pre-proof). Very good news on the efficacy of half-dose of the Moderna vaccine (50 µg vs 100 µg) for ±65 years of age. 2) mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants …we assessed the neutralizing capacity of sera from human subjects or non-human primates (NHPs) that received mRNA-1273. No significant impact on neutralization against the B.1.1.7 variant was detected in either case, however reduced neutralization was measured against the mutations present in